The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in ...
The phase 3 ATOMIC trial is changing the way we treat stage III dMMR colon cancer. In this video, Dr. Sinicrope breaks down ...
Six months of chemotherapy in low-risk stage 3 colorectal cancer patients increases neuropathy compared to three months. IDEA collaboration found similar survival outcomes between three and six months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results